Erratum to: Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.

B. Milojkovic Kerklaan; V. Dieras; C. Le Tourneau; M. Mergui-Roelvink; AD Huitema; H. Rosing; J.H. Beijnen; S. Marreaud; A.S. Govaerts; M.J. Piccart-Gebhart; J.H.M. Schellens; A. Awada

doi:10.1007/s00280-012-2064-y

Erratum to: Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.

B. Milojkovic Kerklaan, V. Dieras, C. Le Tourneau, M. Mergui-Roelvink, AD Huitema, H. Rosing, J.H. Beijnen, S. Marreaud, A.S. Govaerts, M.J. Piccart-Gebhart, J.H.M. Schellens, A. Awada

Clinical Pharmacology

extern

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	553
Number of pages	1
Journal	Cancer Chemotherapy and Pharmacology
Volume	71
Issue number	2
DOIs	https://doi.org/10.1007/s00280-012-2064-y
Publication status	Published - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00280-012-2064-y

Cite this

Milojkovic Kerklaan, B., Dieras, V., Le Tourneau, C., Mergui-Roelvink, M., Huitema, AD., Rosing, H., Beijnen, J. H., Marreaud, S., Govaerts, A. S., Piccart-Gebhart, M. J., Schellens, J. H. M., & Awada, A. (2013). Erratum to: Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023. Cancer Chemotherapy and Pharmacology, 71(2), 553. https://doi.org/10.1007/s00280-012-2064-y

@article{2f79fcb8f31a46ba9ae8bec82394752e,

title = "Erratum to: Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.",

author = "{Milojkovic Kerklaan}, B. and V. Dieras and {Le Tourneau}, C. and M. Mergui-Roelvink and AD Huitema and H. Rosing and J.H. Beijnen and S. Marreaud and A.S. Govaerts and M.J. Piccart-Gebhart and J.H.M. Schellens and A. Awada",

year = "2013",

doi = "10.1007/s00280-012-2064-y",

language = "English",

volume = "71",

pages = "553",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "2",

}

Milojkovic Kerklaan, B, Dieras, V, Le Tourneau, C, Mergui-Roelvink, M, Huitema, AD, Rosing, H, Beijnen, JH, Marreaud, S, Govaerts, AS, Piccart-Gebhart, MJ, Schellens, JHM & Awada, A 2013, 'Erratum to: Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.', Cancer Chemotherapy and Pharmacology, vol. 71, no. 2, pp. 553. https://doi.org/10.1007/s00280-012-2064-y

Erratum to: Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023. / Milojkovic Kerklaan, B.; Dieras, V.; Le Tourneau, C. et al.
In: Cancer Chemotherapy and Pharmacology, Vol. 71, No. 2, 2013, p. 553.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Erratum to: Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.

AU - Milojkovic Kerklaan, B.

AU - Dieras, V.

AU - Le Tourneau, C.

AU - Mergui-Roelvink, M.

AU - Huitema, AD

AU - Rosing, H.

AU - Beijnen, J.H.

AU - Marreaud, S.

AU - Govaerts, A.S.

AU - Piccart-Gebhart, M.J.

AU - Schellens, J.H.M.

AU - Awada, A.

PY - 2013

Y1 - 2013

U2 - 10.1007/s00280-012-2064-y

DO - 10.1007/s00280-012-2064-y

M3 - Article

SN - 0344-5704

VL - 71

SP - 553

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 2

ER -